ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
43 announcements with these filters
Piramal Pharma Ltd announces its 6th AGM on 30 July 2026 and releases the FY 2025‑26 Annual Report. Shareholders may view it via QR code or the website.
Piramal Pharma allotted 21,00,000 equity shares at Rs. 10 each to its ESOP Trust. The issuance supports the company's employee incentive plan and increases paid-up capital to ₹2.10 Crore.
Piramal Pharma received permanent revocation of closure directions for its Dahej site from GPCB. Operations continue normally, ensuring sustained manufacturing stability and environmental compliance.
Piramal Pharma submitted its Annual Secretarial Compliance Report for the financial year 2025-26. The report confirms adherence to SEBI regulations with no adverse observations noted.
Piramal Pharma received an Establishment Inspection Report from the US FDA for its Telangana facility. The inspection is successfully closed, ensuring regulatory compliance and operational continuity.
US FDA concluded inspection of Piramal Pharma's Sellersville facility with three observations. Inspectors recommended VAI classification, with no findings relating to data integrity.
Piramal Pharma Limited has updated the contact details for its Key Managerial Personnel (KMP) under SEBI Regulation 30(5). CFO Vivek Valsaraj and Company Secretary Maneesh Sharma are authorized for determining materiality and making stock exchange disclosures.
Piramal Pharma Limited announced a leadership overhaul, appointing Maneesh Sharma as Company Secretary and Compliance Officer, effective April 29, 2026. The board also approved the re-appointment of Nandini Piramal and Peter DeYoung as Executive Directors, alongside Independent Directors Sridhar Gorthi and Peter Stevenson. These changes ensure long-term governance stability and executive continuity.
Piramal Pharma Limited announced its FY26 results, reporting revenue of ₹8,869 Crore. Performance was impacted by inventory destocking and slower inflows, although the company maintained a strong quality track record with zero OAI. Management remains optimistic for FY27 growth driven by the CDMO and CHG businesses.
Piramal Pharma Ltd reported revenue from operations of ₹2,752 Cr (-0.1% YoY) and a net loss of ₹8.8 Cr for Q4 FY26.
Piramal Pharma Limited reported its FY2026 audited financial results, showing standalone annual revenue of ₹4,782.01 Crore and PAT of ₹700.01 Crore. The Board also approved the re-appointment of Ms. Nandini Piramal as Chairperson and Mr. Peter DeYoung as Executive Director, alongside shifting the company's registered office and appointing a new Company Secretary.
Piramal Pharma Limited successfully closed its US FDA inspection at its Lexington, USA manufacturing facility. The US FDA issued an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) classification. This marks the formal and successful conclusion of the inspection initiated in December 2025.
Piramal Pharma Ltd received an improved ESG rating of '64' from NSE Sustainability for FY 2024-25, up from the previous score of 61. The voluntary rating reflects the company's progress in sustainability and responsible operations based on public disclosures.